Synthesis and evaluation of two series of 4′-aza-carbocyclic nucleosides as adenosine A2A receptor agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 3, 2010, Pages 1219-1224

  Beattie, David ^a,b   Brearley, Andrew ^a,b   Brown, Zarin ^a,b   Charlton, Steven J ^a,b   Cox, Brian ^a,b   Fairhurst, Robin A ^a,b   Fozard, John R ^a,b   Gedeck, Peter ^a,b   Kirkham, Paul ^a,b   Meja, Koremu ^a,b   Nanson, Lana ^a,b   Neef, James ^a,b   Oakman, Helen ^a,b   Spooner, Gillian ^a,b   Taylor, Roger J ^a,b   Turner, Robert J ^a,b   West, Ryan ^a,b   Woodward, Hannah ^a,b  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Adenosine A2A receptor agonists; Anti inflammatory; Carbocyclic nucleosides

Indexed keywords

2 HEXYNYL 5' N ETHYLCARBOXAMIDOADENOSINE; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A2A RECEPTOR AGONIST; ANTIINFLAMMATORY AGENT; CARBOCYCLIC NUCLEOSIDE; GW 328267X; PROPIONAMIDE DERIVATIVE; UNCLASSIFIED DRUG; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE A2A RECEPTOR; CARBOXYLIC ACID; HETEROCYCLIC COMPOUND; NUCLEOSIDE; PYRIMIDINE NUCLEOTIDE;

ARTICLE; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; NUCLEAR MAGNETIC RESONANCE; ANIMAL; CHO CELL LINE; COMPARATIVE STUDY; CRICETULUS; HAMSTER; HUMAN; METABOLISM; PROCEDURES; RAT; SYNTHESIS;

ADENOSINE A2 RECEPTOR AGONISTS; ANIMALS; AZA COMPOUNDS; CARBOXYLIC ACIDS; CHO CELLS; CRICETINAE; CRICETULUS; DRUG EVALUATION, PRECLINICAL; HUMANS; NUCLEOSIDES; PYRIMIDINE NUCLEOTIDES; RATS; RECEPTOR, ADENOSINE A2A;

EID: 74049150722     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.11.131     Document Type: Article

References (38)

1. Fredholm B.B., Ijzerman A.P., Jacobson K.A., Klotz K.-N., and Linden J. Pharmacol. Rev. 53 (2001) 527
2. Jacobsen K.A., and Gao Z.G. Nat. Rev. Drug Disc. 5 (2006) 247
3. Haskó G., and Pacher P. J. Leukocyte Biol. 83 (2008) 447
4. Palmer T.M., and Trevethick M.A. Br. J. Pharmacol. 153 (2008) S27
5. vanden Berg M., Hylkema M.N., Versluis M., and Postma D.S. Drugs R D 8 (2007) 13
6. Bonneau O., Wyss D., Ferretti S., Blaydon C., Stevenson C.S., and Trifilieff A. Am. J. Physiol. Lung Cell Mol. Physiol. 290 (2006) L1036
7. Fozard J.R., Ellis K.M., Villela Dantas M.F., Tigani B., and Mazzoni L. Eur. J. Pharmacol. 438 (2002) 183
8. Trevethick M.A., Mantell S.J., Stuart E.F., Barnard A., Wright K.N., and Yeadon M. Br. J. Pharmacol. 155 (2008) 463
9. Mantell S.J., Stephenson P.T., Monaghan S.M., Maw G.N., Trevethick M.A., Yeadon M., Walker D.K., Selby M.D., Batchelor D.V., Rozze S., Chavaroche H., Lemaitre A., Wright K.N., Whitlock L., Stuart E.F., Wright P.A., and Macintyre F. Bioorg. Med. Chem. Lett. 19 (2009) 4471
10. Mantell S.J., Stephenson P.T., Monaghan S.M., Maw G.N., Trevethick M.A., Yeadon M., Keir R.F., Walker D.K., Jones R.M., Selby M.D., Batchelor D.V., Rozze S., Chavaroche H., Hobson T.J., Dodd P.G., Lemaitre A., Wright K.N., and Stuart E.F. Bioorg. Med. Chem. Lett. 18 (2008) 1284
11. Luijk B., vanden Berge M., Kerstjens H.A.M., Postma D.S., Cass L., Sabin A., and Lammers J.-W.J. Allergy 63 (2008) 75
12. Diniz C., Borges F., Santana L., Uriarte E., Oliveira J.M.A., Gonçalves J., and Fresco P. Curr. Pharm. Des. 14 (2008) 1968
13. Cristalli G., Eleuteri A., Vittori S., Volpini R., Lohse M.J., and Klotz K.-N. J. Med. Chem. 35 (1992) 2363
14. Hutchison A.J., Webb R.L., Oei H.H., Ghai G.R., Zimmerman M.B., and Williams M. J. Pharmacol. Exp. Ther. 251 (1989) 47
15. Stein, H. H.; Prasad, R. N. Adenosine-5′-Carboxylic Acid Amides. U.S. Patent 3,914,415, Oct. 21, 1975.
16. Bevan N., Butchers P.R., Cousins R., Coates J., Edgar E.V., Morrison V., Sheehan M.J., Reeves J., and Wilson D.J. Eur. J. Pharmacol. 564 (2007) 219
17. Chan, C.; Cousins, R. P. C.; Cox, B. 2-(Purin-9-yl)-tertrahydrofuran-3,4-diol derivatives. WO 99/38877, Aug. 5, 1999.
18. Electron density calculations were carried out using Jaguar 7.5 from the Schrödinger 2008 modelling suite software to build and minimise the 4′-substituents. For the minimisation: density functional theory was used with the B3LYP functional and 6-311G** basis sets. The default settings were used with an accuracy level of 'accurate'. For the final geometry the electrostatic potential was calculated and displayed. For the images the range of the colour ramp was set the same for all of the three substituents shown in Figure 2.
19. Tuccinardi T., Ortore G., Manera C., Saccomanni G., and Martinelli A. Eur. J. Med. Chem. 41 (2006) 321
20. Kim S.-K., Gao Z.-G., Van Rompaey P., Gross A.S., Chen A., Van Calenbergh S., and Jacobsen K.A. J. Med. Chem. 46 (2003) 4847
21. Ando T., Kojima K., Chahota P., Kozaki A., Milind N.D., and Kitade Y. Bioorg. Med. Chem. Lett. 18 (2008) 2615
22. Yang M., and Schneller S.W. Bioorg. Med. Chem. Lett. 13 (2005) 877
23. Ghosh A., Miller M.J., De Clercq E., and Balzarini J. Nucleosides Nucleotides 18 (1999) 217
24. Hegde V.R., Seley H.K., and Schneller S.W. J. Org. Chem. 63 (1998) 7092
25. Mulvihill M.J., and Miller M.J. Tetrahedron 54 (1998) 6605
26. Donohoe T.J., Blades K., Moore P.R., Waring M.J., Winter J.J.G., Helliwell M., Newcombe N.J., and Stemp G. J. Org. Chem. 67 (2002) 7946
27. Ghosh A., Ritter A.R., and Miller M.J. J. Org Chem. 60 (1995) 5808
28. Siddiqi S.M., Jacobson K.A., Esker J.L., Olah M.E., Ji X., Melman N., Tiwari K.N., Secrist III J.A., Schneller S.W., Cristalli G., Stiles G.L., Johnson C.R., and Ijzerman A.P. J. Med. Chem. 38 (1995) 1174
29. Wuts P.G.M., Ashford S.W., Anderson A.M., and Atkins J.R. Org. Lett. 5 (2003) 1483
30. Keeling S.E., Albinson F.D., Ayres B.E., Butchers P.R., Chambers C.L., Cherry P.C., Ellis F., Ewan G.B., Gregson M., Knight J., Mills K., Ravenscroft P., Reynolds L.H., Sanjar S., and Sheehan M.J. Bioorg. Med. Chem. Lett. 10 (2000) 403
31. Jain R., and Cohen L.A. Tetrahedron 52 (1996) 5363
32. 6 cells/ml (neutrophil purity >97%) and 50 μl dispensed per assay well (Sigmacote® treated). Test article was added (50 μl) and after a 30 min preincubation at 37 °C solutions of lucigenin (50 μl of a 400 μM solution) and then formylated tripeptide MLP (fMLP) (50 μl of a 4 μM solution) were added. Release of reactive oxygen species was assessed from the chemiluminescence generated over the 4 min incubation period following fMLP addition.
33. Volpini R., Costanzi S., Lambertucci C., Taffi S., Vittori S., Klotz K.-N., and Cristalli G. J. Med. Chem. 45 (2002) 3271
34. Melman A., Gao Z.-G., Kumar D., Wan T.C., Gizewski E., Auchampach J.A., and Jacobsen K.A. Bioorg. Med. Chem. Lett. 18 (2008) 2813
35. Cappellacci L., Franchetti P., Vita P., Petrelli R., Lavecchia A., Costa B., Spinetti F., Martini C., Klotz K.-N., and Grifantini M. Bioorg. Med. Chem. 16 (2008) 336
36. Gao Z.-G., Blaustein J.B., Gross A.S., Melman N., and Jacobson K.A. Biochem. Pharmacol. 65 (2003) 1675
37. Linden J., and Jacobson K.A. Dev. Cardiovasc. Med. 209 (1998) 1
38. 2A receptor mediated.